Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.

Abstract

No clinical breakpoints are available to delineate antifungal drug efficacy in non-Aspergillus invasive mold infections (NAIMIs). In this analysis of 39 NAIMI episodes, the MIC of the first-line antifungal drug was the most important predictor of therapeutic response. For amphotericin B, an MIC of ≤0.5 μg/ml was significantly associated with better 6-week outcomes.

DOI: 10.1128/JCM.00318-16

Statistics

05002017
Citations per Year

82 Citations

Semantic Scholar estimates that this publication has 82 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Lamoth2016RoleOA, title={Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.}, author={Fr{\'e}d{\'e}ric Lamoth and Lauro Damonti and Barbara D. Alexander}, journal={Journal of clinical microbiology}, year={2016}, volume={54 6}, pages={1638-40} }